Findings

What do systematic reviews say?

5 questions · 5 findings · 3 reviews · Oral medicine and oral cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 5 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Prophylactic valaciclovir (lower dose) vs Prophylactic valaciclovir (higher dose)

Presence/absence of HSV oral lesions · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)

Prophylactic valaciclovir (lower dose) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (higher dose); GRADE not reported.

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
RR 0.23 [0.05, 1.03]
2 studies · 181 participants
GRADE not reported

Prophylactic valaciclovir (lower dose) vs Prophylactic valaciclovir (higher dose)

Viral isolates · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
Orlowski 2004: 182 throat swabs performed for patients receiving 500 mg of valaciclovir (n = 40) and 198 swabs for those receiving 1000 mg (n = 41); all of the cultures proved negative (1 trial, 81; not estimable).
1 study · 81 participants
GRADE not reported

Prophylactic valaciclovir (lower dose) vs Prophylactic valaciclovir (higher dose)

Adverse effects · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
One study reported adverse effects (Warkentin 2002). Twenty patients allocated to receive high dose valaciclovir reported adverse effects (42%); for the low dose group this number was 27 (52%). Adverse effects were…
1 study · 100 participants
GRADE not reported

Low dose rate interstitial radiotherapy vs High dose rate interstitial radiotherapy

Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…

Low dose rate interstitial radiotherapy showed no clear difference in locoregional control compared with high dose rate interstitial radiotherapy; GRADE not reported.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
HR 1.00 [0.16, 6.44]
1 study · 59 participants
GRADE not reported

Intestinal trefoil factor (ITF), lower dose (336 mg) vs Intestinal trefoil factor (ITF), higher dose (2688 mg)

Oral mucositis (any severity) · Adults receiving chemotherapy alone for colorectal cancer

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Insufficient evidence to determine whether lower (336 mg) or higher (2688 mg) dose performs better (Analyses 11.1 to 11.3); no pooled estimate reported
1 study · 66 participants
GRADE not reported